Search

Your search keyword '"Facchinelli, Davide"' showing total 39 results
Start Over Author "Facchinelli, Davide"
39 results on '"Facchinelli, Davide"'

1. Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group

Author

Forghieri, Fabio, Bettelli, Francesca, Sgromo, Simona, Nadali, Gianpaolo, Del Principe, Maria Ilaria, Buzzatti, Elisa, Farina, Francesca, Cesini, Laura, Giordano, Antonio, Criscuolo, Marianna, Facchinelli, Davide, Piedimonte, Monica, Sartor, Chiara, De Marchi, Roberta, Delia, Mario, Mosna, Federico, Cudillo, Laura, Tolomelli, Giulia, Basilico, Claudia Maria, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Lessi, Federica, Finizio, Olimpia, Zannetti, Beatrice Anna, Santoni, Adele, Fazi, Paola, Marchesi, Francesco, Venditti, Adriano, Candoni, Anna, Luppi, Mario, Busca, Alessandro, and Pagano, Livio

Published
2024
Full Text
View/download PDF

2. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements

Author

Bonifacio, Massimiliano, Scaffidi, Luigi, Miggiano, Maria Cristina, Facchinelli, Davide, Tosoni, Luca, Pezone, Sara, Griguolo, Davide, Ciotti, Giulia, Danini, Marco, Bernardelli, Andrea, Bresciani, Rita, Cavraro, Monica, Crosera, Lara, De March, Elena, Dell’Eva, Michele, Dorotea, Laura, Frison, Luca, Furlani, Lara, Gianesello, Ilaria, Lovato, Ester, Marchetti, Elena, Morelli, Gianluca, Mullai, Rikard, Pizzano, Umberto, Zoletto, Simone, Fanin, Renato, Krampera, Mauro, Trentin, Livio, Calistri, Elisabetta, Carli, Giuseppe, Binotto, Gianni, and Tiribelli, Mario

Published
2024
Full Text
View/download PDF

4. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

Author

Autore, Francesco, Visentin, Andrea, Deodato, Marina, Vitale, Candida, Galli, Eugenio, Fresa, Alberto, Fazzi, Rita, Sanna, Alessandro, Olivieri, Jacopo, Scortechini, Ilaria, Del Principe, Maria Ilaria, Sportoletti, Paolo, Schiattone, Luana, Maschio, Nilla, Facchinelli, Davide, Marchesi, Francesco, Coscia, Marta, Tedeschi, Alessandra, Trentin, Livio, Innocenti, Idanna, Candoni, Anna, Busca, Alessandro, Pagano, Livio, Laurenti, Luca, Pagano, Livio (ORCID:0000-0001-8287-928X), Laurenti, Luca (ORCID:0000-0002-8327-1396), Autore, Francesco, Visentin, Andrea, Deodato, Marina, Vitale, Candida, Galli, Eugenio, Fresa, Alberto, Fazzi, Rita, Sanna, Alessandro, Olivieri, Jacopo, Scortechini, Ilaria, Del Principe, Maria Ilaria, Sportoletti, Paolo, Schiattone, Luana, Maschio, Nilla, Facchinelli, Davide, Marchesi, Francesco, Coscia, Marta, Tedeschi, Alessandra, Trentin, Livio, Innocenti, Idanna, Candoni, Anna, Busca, Alessandro, Pagano, Livio, Laurenti, Luca, Pagano, Livio (ORCID:0000-0001-8287-928X), and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2024

5. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience

Author

Filì, Carla, Candoni, Anna, Zannier, Maria Elena, Olivieri, Jacopo, Imbergamo, Silvia, Caizzi, Manuela, Nadali, Gianpaolo, Di Bona, Eros, Ermacora, Anna, Gottardi, Michele, Facchinelli, Davide, Ciancia, Rosanna, Lazzarotto, Davide, Dubbini, Maria Vittoria, Festini, Gianluca, Gherlinzoni, Filippo, Michieli, Maria Grazia, Semenzato, Gianpietro, and Fanin, Renato

Published
2019
Full Text
View/download PDF

6. Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Author

Autore, Francesco, primary, Visentin, Andrea, additional, Deodato, Marina, additional, Vitale, Candida, additional, Galli, Eugenio, additional, Fresa, Alberto, additional, Fazzi, Rita, additional, Sanna, Alessandro, additional, Olivieri, Jacopo, additional, Scortechini, Ilaria, additional, Del Principe, Maria Ilaria, additional, Sportoletti, Paolo, additional, Schiattone, Luana, additional, Maschio, Nilla, additional, Facchinelli, Davide, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Innocenti, Idanna, additional, Candoni, Anna, additional, Busca, Alessandro, additional, Pagano, Livio, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

8. P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY

Author

Autore, Francesco, primary, Visentin, Andrea, additional, Deodato, Marina, additional, Vitale, Candida, additional, Galli, Eugenio, additional, Fresa, Alberto, additional, Fazzi, Rita, additional, Sanna, Alessandro, additional, Olivieri, Jacopo, additional, Scortechini, Ilaria, additional, Principe, Maria Ilaria DEL, additional, Sportoletti, Paolo, additional, Schiattone, Luana, additional, Maschio, Nilla, additional, Facchinelli, Davide, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Innocenti, Idanna, additional, Candoni, Anna, additional, Busca, Alessandro, additional, Pagano, Livio, additional, and Laurenti, Luca, additional

Published
2023
Full Text
View/download PDF

9. P1183: CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS AND AT RELAPSE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE “RETE EMATOLOGICA VENETA” (T-REV PROJECT).

Author

Riva, Marcello, primary, Chiara Tisi, Maria, additional, Facchinelli, Davide, additional, Scapinello, Greta, additional, Schena, Alberto, additional, Marino, Dario, additional, Finotto, Silvia, additional, Romano, Leila, additional, Cavallari, Maurizio, additional, Borghero, Carlo, additional, Bassan, Renato, additional, Krampera, Mauro, additional, Gherlinzoni, Filippo, additional, Trentin, Livio, additional, Tosetto, Alberto, additional, Maria Stefani, Piero, additional, Piazza, Francesco, additional, and Visco, Carlo, additional

Published
2023
Full Text
View/download PDF

11. P1691: PALLIATIVE CARE IN HEMATOLOGICAL PATIENTS IS RELATED TO LESS AGGRESSIVE TREATMENT IN THE END-OF-LIFE, A RETROSPECTIVE STUDY.

Author

Facchinelli, Davide, primary, Greco, Corinna, additional, Rigno, Manuela, additional, Menon, Daniela, additional, Manno, Pietro, additional, Potenza, Leonardo, additional, Cartoni, Claudio, additional, Riva, Marcello, additional, Verde, Laura Dalla, additional, Varalta, Anna, additional, and Tosetto, Alberto, additional

Published
2023
Full Text
View/download PDF

13. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Author

Cattaneo, Chiara, primary, Marchesi, Francesco, additional, Terrenato, Irene, additional, Bonuomo, Valentina, additional, Fracchiolla, Nicola Stefano, additional, Delia, Mario, additional, Criscuolo, Marianna, additional, Candoni, Anna, additional, Prezioso, Lucia, additional, Facchinelli, Davide, additional, Pasciolla, Crescenza, additional, Del Principe, Maria Ilaria, additional, Dargenio, Michelina, additional, Buquicchio, Caterina, additional, Mitra, Maria Enza, additional, Farina, Francesca, additional, Borlenghi, Erika, additional, Nadali, Gianpaolo, additional, Gagliardi, Vito Pier, additional, Fianchi, Luana, additional, Sciumè, Mariarita, additional, Menna, Pierantonio, additional, Busca, Alessandro, additional, Rossi, Giuseppe, additional, and Pagano, Livio, additional

Published
2022
Full Text
View/download PDF

14. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma

Author

Bega, Giulia, primary, Olivieri, Jacopo, additional, Riva, Marcello, additional, Scapinello, Greta, additional, Paolini, Rossella, additional, Finotto, Silvia, additional, Sartori, Roberto, additional, Lucchini, Elisa, additional, Guandalini, Gianmarco, additional, Facchinelli, Davide, additional, Tisi, Maria Chiara, additional, Basso, Marco, additional, Ballotta, Laura, additional, Piazza, Francesco, additional, Ferrarini, Isacco, additional, and Visco, Carlo, additional

Published
2021
Full Text
View/download PDF

15. Primary Pancreatic Lymphoma: Recommendations for Diagnosis and Management

Author

Facchinelli,Davide, Boninsegna,Enrico, Visco,Carlo, and Tecchio,Cristina

Subjects
Journal of Blood Medicine
Abstract

Davide Facchinelli,1 Enrico Boninsegna,2 Carlo Visco,3 Cristina Tecchio3 1Hematology Unit, Ospedale San Bortolo, Vicenza, Italy; 2Department of Radiology, Azienda Socio Sanitaria Territoriale, Mantova, Italy; 3Hematology and Bone Marrow Transplant Unit, Department of Medicine, University of Verona, Verona, ItalyCorrespondence: Davide FacchinelliHematology Unit, Ospedale San Bortolo, Vicenza, ItalyEmail davide.facchinelli@aulss8.veneto.itBackground: Primary pancreatic lymphoma (PPL) is a rare disease representing 0.1% of all malignant lymphomas, which lacks well-defined diagnostic and therapeutic protocols. We conducted a systematic review to analyze demographic, diagnostic and therapeutic features of PPL.Methods: This review identified small series and single case reports. Sources were MEDLINE, PubMed, and the Cochrane library from January 2001 to December 2020. Data were screened, extracted and the risk of bias analyzed by three independent reviewers.Results: A total of 107 eligible papers (17 small series, 90 single case reports) describing 266 patients were identified. Patients had a median age of 53.1 (range 3– 86) years and were males in 64.6% of cases. Abdominal pain and jaundice were the most common presenting symptoms, affecting 75.3% and 41.8% of patients, respectively. PPL had a median size of 60.6 mm (range 16– 200) and it was localized in the pancreatic head in 63.7% of cases. At diagnosis most patients underwent ultrasonography followed by computed tomography. PPL typically showed low echogenicity, and lower contrast enhancement than solid tumors. Histopathological specimens were obtained by percutaneous or endoscopic biopsies in 47.7% of patients; abdominal surgery was performed in 33.5% of cases. Overall, diffuse large B-cell lymphoma was the most frequent histological diagnosis (53.6%). However, patients aged < 18 years were affected by Burkitt lymphoma in 52.4% of cases. Most patients (53.6%) received immunochemotherapy (IC) or IC plus radiotherapy (14%). Demolitive surgery appeared to be associated with impaired survival. Central nervous system (CNS) relapse or progression was observed in 20% of patients.Conclusion: PPL is a rare entity, with some peculiar features at modern imaging. For diagnostic purposes percutaneous or endoscopic biopsies might be preferable, as opposed to surgery. No definite data is available about the optimal treatment, which should be tailored on the histological type and associated with CNS prophylaxis.Keywords: primary pancreatic lymphoma, diffuse large B cell lymphoma, Burkitt lymphoma

Published
2021

16. Isolated cerebellar progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation: focus on imaging

Author

Borghero Carlo, Mazzai Linda, Vitale Valerio, Iannucci Giuseppe, Facchinelli Davide, and Ruggeri Marco

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Opportunistic infection, medicine.medical_treatment, JC virus, Hematopoietic stem cell transplantation, medicine.disease_cause, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, CSF albumin, Immunodeficiency, medicine.diagnostic_test, business.industry, Progressive multifocal leukoencephalopathy, Hematopoietic Stem Cell Transplantation, Leukoencephalopathy, Progressive Multifocal, Myeloid leukemia, Magnetic resonance imaging, General Medicine, Middle Aged, medicine.disease, Prognosis, Magnetic Resonance Imaging, Leukemia, Myeloid, Acute, Oncology, business, 030217 neurology & neurosurgery
Abstract

Introduction: Progressive multifocal leukoencephalopathy (PML) is caused by JC virus opportunistic infection in the setting of immunodeficiency. Typical imaging features are multifocal and asymmetric lesions within supratentorial subcortical white matter in parieto-occipital regions. Case description: A 47-year-old patient experienced a relapse of acute myeloid leukemia 21 months after hematopoietic stem cell transplantation. He also had visual impairment and magnetic resonance imaging showed an isolated cerebellar lesion without mass effect or enhancement. Common opportunistic infections and leukemic central nervous system involvement were excluded by cerebrospinal fluid (CSF) analysis. Given the worsening clinical and radiologic scenario, PML was suspected, and CSF protein chain reaction analysis was positive for JC virus. Conclusions: Given its potential curability, PML should be thoroughly investigated in patients with hematologic neoplasms and atypical isolated cerebellar presentation.

Published
2021

17. Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study

Author

Marchesini, Gessica, Nadali, Gianpaolo, Facchinelli, Davide, Candoni, Anna, Cattaneo, Chiara, Cuccaro, Annarosa, Fanci, Rosa, Farina, Francesca, Lessi, Federica, Visentin, Andrea, Marchesi, Francesco, Prezioso, Lucia, Spolzino, Angelica, Tisi, Maria Chiara, Trastulli, Fabio, Verga, Luisa, Dargenio, Michela, Busca, Alessandro, Pagano, Livio, Pagano, Livio (ORCID:0000-0001-8287-928X), Marchesini, Gessica, Nadali, Gianpaolo, Facchinelli, Davide, Candoni, Anna, Cattaneo, Chiara, Cuccaro, Annarosa, Fanci, Rosa, Farina, Francesca, Lessi, Federica, Visentin, Andrea, Marchesi, Francesco, Prezioso, Lucia, Spolzino, Angelica, Tisi, Maria Chiara, Trastulli, Fabio, Verga, Luisa, Dargenio, Michela, Busca, Alessandro, Pagano, Livio, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

no abstract

Published
2020

19. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial

Author

Zucca, Emanuele, primary, Cascione, Luciano, additional, Ruberto, Teresa, additional, Facchinelli, Davide, additional, Schär, Sämi, additional, Hayoz, Stefanie, additional, Dirnhofer, Stefan, additional, Giovanella, Luca, additional, Bargetzi, Mario, additional, Mamot, Christoph, additional, and Ceriani, Luca, additional

Published
2020
Full Text
View/download PDF

20. Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome

Author

Facchinelli, Davide, primary, Sina, Sokol, additional, Boninsegna, Enrico, additional, Borin, Alex, additional, Tisi, Maria C., additional, Piazza, Francesco, additional, Scapinello, Greta, additional, Maiolo, Elena, additional, Hohaus, Stefan, additional, Zamò, Alberto, additional, Merli, Michele, additional, Stefani, Piero M., additional, Mellone, Federica, additional, Basso, Marco, additional, Sartori, Roberto, additional, Rusconi, Chiara, additional, Parisi, Alice, additional, Manfrin, Erminia, additional, Krampera, Mauro, additional, Ruggeri, Marco, additional, Visco, Carlo, additional, and Tecchio, Cristina, additional

Published
2020
Full Text
View/download PDF

24. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.

Author

Marchesini, Gessica, Nadali, Gianpaolo, Facchinelli, Davide, Candoni, Anna, Cattaneo, Chiara, Laurenti, Luca, Fanci, Rosa, Farina, Francesca, Lessi, Federica, Visentin, Andrea, Marchesi, Francesco, Prezioso, Lucia, Spolzino, Angelica, Tisi, Maria Chiara, Trastulli, Fabio, Picardi, Marika, Verga, Luisa, Dargenio, Michelina, Busca, Alessandro, and Pagano, Livio

Subjects
MYCOSES, OPPORTUNISTIC infections, BACTERIAL diseases, VIRUS diseases, LYMPHOPROLIFERATIVE disorders
Abstract

Summary: We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P < 0·001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13·7% vs. 3·8% respectively; P = 0·18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs

Author

Facchinelli, Davide, Marchesini, Gessica, Nadali, Gianpaolo, Pagano, Livio, Pagano, Livio (ORCID:0000-0001-8287-928X), Facchinelli, Davide, Marchesini, Gessica, Nadali, Gianpaolo, Pagano, Livio, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

This review summarizes the more recent evidence about epidemiology and risk factors for invasive fungal infections (IFI) in patients affected by Chronic Lymphocytic Leukemia (CLL), indolent Non Hodgkin Lymphoma (iNHL) and Multiple Myeloma (MM).Despite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemia has been published while little information is available on the incidence of IFI in chronic lymphoproliferative disorders (CLD).New drugs are now available for treatment of lymphoproliferative disorders which may cause suppression of humoral immunity, cellular immunity, and deficiency of white blood cells, increasing the risk for infections which remain the leading cause of mortality in these patients.

Published
2018

26. Infections in Patients with Lymphoproliferative Diseases Treated with Target Therapy. Italian Multicentric Retrospective Study Seifem 2017

Author

Nadali, Gianpaolo, primary, Marchesini, Gessica, additional, Facchinelli, Davide, additional, Farina, Francesca, additional, Tisi, Maria Chiara, additional, Lessi, Federica, additional, Marchesi, Francesco, additional, Cattaneo, Chiara, additional, Candoni, Anna, additional, Fanci, Rosa, additional, Prezioso, Lucia, additional, Verga, Luisa, additional, Laurenti, Luca, additional, Trastulli, Fabio, additional, Picardi, Marco, additional, Del Principe, Maria Ilaria, additional, Silva, Ronaldo, additional, and Busca, Alessandro, additional

Published
2018
Full Text
View/download PDF

32. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients

Author

Marini, Olivia, primary, Spina, Cecilia, additional, Mimiola, Elda, additional, Cassaro, Adriana, additional, Malerba, Giovanni, additional, Todeschini, Giuseppe, additional, Perbellini, Omar, additional, Scupoli, Maria, additional, Carli, Giuseppe, additional, Facchinelli, Davide, additional, Cassatella, Marco, additional, Scapini, Patrizia, additional, and Tecchio, Cristina, additional

Published
2016
Full Text
View/download PDF

33. A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Author

Scarfo, Lydia, Coscia, Marta, Molteni, Alfredo, Rambaldi, Alessandro, Marasca, Roberto, Steffanoni, Sara, Murru, Roberta, Maschio, Nilla, Scortechini, Ilaria, Gambacorti-Passerini, Carlo, Pennese, Elsa, Trentin, Livio, Moia, Riccardo, Farina, Lucia, Innao, Vanessa, Musto, Pellegrino, Sanna, Alessandro, Facchinelli, Davide, Falcucci, Paolo, Pini, Massimo, Laurenti, Luca, Varettoni, Marzia, Angeletti, Ilaria, Orsucci, Lorella, Rago, Angela, D'Arena, Giovanni, Melillo, Lorella Maria Antonia, Maggi, Alessandro, Ilariucci, Fiorella, Massaia, Massimo, Pastore, Domenico, Vallisa, Daniele, Fazi, Paola, Piciocchi, Alfonso, Messina, Monica, Paoloni, Francesca Paola, Foà, Robin, Del Giudice, Ilaria, Rigolin, Gian Matteo, Cuneo, Antonio, and Ghia, Paolo

Abstract

In recent years the management of patients (pts) with chronic lymphocytic leukemia (CLL) has benefited from a deeper knowledge of the mechanisms underlying the disease and from the development of novel therapeutic approaches. That notwithstanding, local and national accessibility to drugs and tests may lead to distinct “real-world” practices in terms of management of pts that are worth of being recorded and compared to understand the degree of reproducibility and applicability of international guidelines. This could also be relevant for the design of future clinical trials, more tailored to the true patient's needs. To this end, within the GIMEMA cooperative study group the observational retrospective and prospective CLL2121 study (NCT04867915) has been designed with the objective of evaluating the diagnosis and management of CLL in all hematological centers in Italy through the assessment of: 1) the methods and the actual diagnostic/prognostic work-up capacity; 2) the algorithms applied to define disease progression and treatment requirements with respect to national and international guidelines; 3) the clinical and biological variables not strictly associated with CLL, but capable of influencing the clinical course and overall survival; 4) the true incidence of some rarer complications associated with CLL. The study consists of a collection of clinico-biological data from all pts with newly diagnosed CLL, small lymphocytic lymphoma (SLL) or CLL-like monoclonal B-cell lymphocytosis (MBL), according to the iwCLL 2018 criteria in Italy. The retrospective part aims at including all cases followed at the participating centers with a diagnosis between January 2010 and September 2021, while the prospective part will include all pts with a documented diagnosis of CLL, SLL or MBL between September 2021 and September 2025. In this pilot analysis of the study, we examined pts' demographics, diagnosis, treatment line and type. Data were collected using the REDCap electronic data capture platform, analyzed using the SAS software v.9.4 and reported as numbers and frequencies. Between 2 November 2021 and 28 June 2023, 3294 eligible pts were enrolled in 75 hematology centers (out of the total of 110 centers who will be activated during the study) across the entire Italian territory. At the time of the present report, 3033 pts had clinical data available for our preliminary analysis. The vast majority of pts registered (N=2599, 85.7%) belonged to the retrospective cohort while only a minority (N=434, 14.3%) to the prospective cohort. Pts had a median age of 68 years ranging from 29 to 97; 60% of pts were males. 2630 pts (86.8%) had a diagnosis of CLL, 187 (6.2%) of SLL and 214 (7.0%) of MBL (2 missing information). Among those with available results 112 pts (12.6%) were TP53mutated, 526 (45.6%) del(13q) positive, 174 (14.9%) del(11q) positive, 142 (11.9%) del(17p) positive and 226 (20.4%) presented a trisomy 12. The majority of pts (57.6%) were untreated, while 42.4% have been treated. Within the latter subset, 67.3% of pts have received one line of therapy, 21.4% 2 lines of therapy, 11.3% ≥3 lines of therapy. The most common therapeutic regimens were the combination of chemotherapy with an anti-CD20 antibody (39.3%), mainly rituximab, and those based on BTK inhibitors (33.3%), mainly ibrutinib. Chemotherapy alone was used in 12% of pts. Only 5% of pts was treated with the BCL2 inhibitor venetoclax. In the remaining 10% of pts, other approaches were used. This is the initial report of a nation-based real-world data collection aimed at describing the biological and clinical features of pts diagnosed with CLL in virtually all Italian hematology centers starting from 2010. The pattern of treatments highlighted in our preliminary analysis, with a wide use of the watch & wait policy and of chemoimmunotherapy, will help understand how the introduction of novel therapies impacted treatment habits also in light of the timing of the local reimbursement policy. The different time of drug access in Italy, typically delayed after the EU approval, may also have affected the limited use of venetoclax-based treatment. The continuous accrual of pts in this study will allow to obtain a close-to-registry vision of CLL management in Italy over time, in terms of coverage of the entire country but enriched with the granularity of the data and flexibility of the collection typical of a real-world study.

Published
2023
Full Text
View/download PDF

34. Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Author

Autore, Francesco, Visentin, Andrea, Deodato, Marina, Vitale, Candida, Galli, Eugenio, Fresa, Alberto, Fazzi, RITA, Sanna, Alessandro, Olivieri, Jacopo, Scortechini, Ilaria, Del Principe, Maria Ilaria, Sportoletti, Paolo, Schiattone, Luana, Maschio, Nilla, Facchinelli, Davide, Coscia, Marta, Tedeschi, Alessandra, Trentin, Livio, Innocenti, Idanna, Candoni, Anna, Busca, Alessandro, Pagano, Livio, and Laurenti, Luca

Abstract

Introduction.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has led to a significant increase of morbidity worldwide. A recent meta-analysis showed a high case fatality rate in hospitalized patients with hematological malignancies and published reports indicated high rates also in chronic lymphocytic leukemia patients (CLL) patients.

Published
2023
Full Text
View/download PDF

35. Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy

Author

Borlenghi, Erika, Filì, Carla, Basilico, Claudia, Bernardi, Massimo, Caizzi, Manuela, Ciancia, Rosanna, Di Bona, Eros, Ermacora, Anna, Facchinelli, Davide, Fracchiolla, Nicola, Fumagalli, Monica, Gottardi, Michele, Imbergamo, Silvia, Lambertenghi, Daniela, Molteni, Alfredo, Petullà, Marta, Riva, Marta, Todisco, Elisabetta, Rossi, Giuseppe, and Candoni, Anna

Published
2017
Full Text
View/download PDF

36. Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

Author

Facchinelli, Davide, Parisi, Alice, Krampera, Mauro, and Veneri, Dino

Abstract

Purpose: We assessed the frequency of triple-positive serology (viral capsid antigen [VCA]–immunoglobulin G [IgG], VCA–immunoglobulin M, Epstein-Barr nuclear antigen–IgG) for Epstein-Barr virus (EBV) in a small number of patients with angioimmunoblastic T-cell lymphoma (AITL) at disease onset.Methods: Nine patients with newly diagnosed AITL were retrospectively enrolled in the present study. For all of them, EBV serology data were available.Results: Of 9 patients, 7 (77.7%) had a triple-positive serology (VCA-IgG, VCA-IgM, EBNA-IgG ) for EBV. These patients were characterized by bone marrow involvement, high incidence of thrombocytopenia, and poor prognosis according to Revised International Prognostic Index and Prognostic Index for Angioimmunoblastic T-cell Lymphoma scores.Conclusion: Assessment of both viremia and serology for EBV could be useful in patients with clinical and laboratory data suggesting lymphoma diagnosis; furthermore, although our data need to be validated in a larger cohort of patients, triple positivity for EBV serology might help to direct the diagnosis toward AITL.

Published
2020
Full Text
View/download PDF

37. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.

Author

Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri J, Scortechini I, Del Principe MI, Sportoletti P, Schiattone L, Maschio N, Facchinelli D, Marchesi F, Coscia M, Tedeschi A, Trentin L, Innocenti I, Candoni A, Busca A, Pagano L, and Laurenti L

Subjects
Humans, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Risk Factors, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Antineoplastic Agents therapeutic use, Sulfonamides
Published
2024
Full Text
View/download PDF

38. Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study.

Author

Marchesini G, Nadali G, Facchinelli D, Candoni A, Cattaneo C, Cuccaro A, Fanci R, Farina F, Lessi F, Visentin A, Marchesi F, Prezioso L, Spolzino A, Tisi MC, Trastulli F, Verga L, Dargenio M, Busca A, and Pagano L

Subjects
Brentuximab Vedotin, Humans, Retrospective Studies, Hodgkin Disease complications, Hodgkin Disease drug therapy, Immunoconjugates adverse effects, Lymphoproliferative Disorders drug therapy
Published
2020
Full Text
View/download PDF

39. Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs.

Author

Facchinelli D, Marchesini G, Nadali G, and Pagano L

Abstract

This review summarizes the more recent evidence about epidemiology and risk factors for invasive fungal infections (IFI) in patients affected by Chronic Lymphocytic Leukemia (CLL), indolent Non Hodgkin Lymphoma (iNHL) and Multiple Myeloma (MM). Despite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemia has been published while little information is available on the incidence of IFI in chronic lymphoproliferative disorders (CLD). New drugs are now available for treatment of lymphoproliferative disorders which may cause suppression of humoral immunity, cellular immunity, and deficiency of white blood cells, increasing the risk for infections which remain the leading cause of mortality in these patients., Competing Interests: Competing interests: The authors have declared that no competing interests exist.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results